Microparticles containing leuprolide and methods for producing same
Microparticles with leuprolide and biodegradable polymers address the issue of frequent injections by ensuring sustained release and uniform distribution, maintaining effective drug concentration for over a month without initial over-release.
Patent Information
- Application Number
- JP2024532892
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-12-03
- Filing Date
- 2022-11-28
- Publication Date
- 2024-11-08
AI Technical Summary
Current LHRH agonists like leuprolide acetate have low oral bioavailability and require frequent injections due to short half-life, leading to initial over-release and side effects, necessitating sustained-release formulations that maintain effective blood concentration for extended periods.
Microparticles containing leuprolide and biodegradable polymers with controlled release rates, manufactured through a microchannel process, ensuring uniform size and smooth surface, preventing initial over-release and sustaining drug efficacy for over a month.
The microparticles provide a sustained release of leuprolide for over a month, reducing frequency of injections and minimizing side effects by maintaining effective blood concentration without initial over-release.
Smart Images

Figure 2024541649000001_ABST
Abstract
Description
[Technical field]
[0001] The present invention relates to microparticles containing leuprolide and a method for producing the same. [Background technology]
[0002] LHRH (luteinizing hormone releasing hormone), also known as GnRH (gonadotropin releasing hormone), is a hypothalamic decapeptide (pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2) that regulates the reproductive system in vertebrates.
[0003] It is released into the capillaries of the hypothalamic-pituitary portal system in the median eminence and infundibular stem. This capillary network allows LHRH to reach the anterior pituitary gland, and a second capillary network to reach gonadotropic target cells. GnRH acts at the membrane level of target cells through a receptor with seven transmembrane segments that couples to phospholipase C through G proteins and increases calcium flux within the cells.
[0004] Such action induces the synthesis and release of the gonadotropic hormones FSH (follicle-stimulating hormone) and LH (luteinizing hormone).LHRH agonists and antagonists have been found to be effective in the treatment of endometriosis, fibroids, polycystic ovarian disease, breast, ovarian and endometrial cancer in women, gonadotropic pituitary desensitization during medically-assisted childbirth protocols, benign prostate and polyplasia and prostate cancer in men, and precocious puberty in men or women.
[0005] Currently, the LHRH agonists (Luteinizing Hormone Releasing Hormone agonists) used are peptide compounds that, due to their low oral bioavailability, must generally be administered by intravenous or subvenous means.
[0006] In addition, LHRH agonists are drugs for late-onset diseases and must be administered for a long period of time. It is known that LHRH agonist drugs require rapid exposure to a sufficient amount of drug in the early stages in order to exert their effects.
[0007] Leuprolide acetate, one of the LHRH agonists, has a short half-life when administered subcutaneously or intramuscularly, and its blood concentration drops rapidly after administration, disappearing within a few hours. This means that it must be administered every day to maintain its efficacy, and this inconvenience is compounded by the fact that it is an injectable drug.
[0008] To remedy this, preparations whose efficacy lasts for four weeks or more after a single administration (sustained-release preparations) have been developed and sold.
[0009] However, it is known that in order for leuprolide acetate to exert its therapeutic effect, a sufficient amount of the drug must be exposed to the target site at the initial stage of administration. Since the blood concentration of leuprolide acetate inhibits circulating sex hormone levels for 2 to 4 weeks after its initial rise, it is known that in order for leuprolide to be effective, a high initial drug release rate from microparticles is preferable.
[0010] Therefore, when leuprolide is administered by injection in all currently available products and the blood concentration of leuprolide is measured, it is known that an initial over-release occurs, and if no initial over-release occurs, the effects of leuprolide are not being expressed. [Prior art documents] [Patent documents]
[0011] [Patent Document 1] Korean Published Application No. 10-2003-0064401 Summary of the Invention [Problem to be solved by the invention]
[0012] The object of the present invention relates to microparticles containing leuprolide and a method for the preparation thereof.
[0013] Another object of the present invention is to provide microparticles containing leuprolide which, when administered by injection, can reduce pain due to the small size of the microparticles, can regulate the release rate of leuprolide at the target site to prevent initial over-release, and can expose a sufficient amount of drug to exert the effects of leuprolide for one month or more.
[0014] Another object of the present invention is to provide a method for preparing microparticles, which have a uniform particle size, a smooth surface, and can exhibit a leuprolide releasing effect for a long period of time. [Means for solving the problem]
[0015] To achieve the above object, the leuprolide-containing microparticles according to one embodiment of the present invention comprise leuprolide and a biodegradable polymer, and the average diameter of the microparticles may be 40 to 100 μm, and the value according to the following formula 1 may be 0.5 to 2.
[0016]
number
[0017] Where: D10 is the diameter of the particle that corresponds to 10% of the maximum value in the cumulative distribution of particles, D50 is the diameter of the particle that corresponds to 50% of the maximum value in the cumulative distribution of particles, D90 is the diameter of particles that corresponds to 90% of the maximum value in a cumulative particle distribution.
[0018] The leuprolide and the biodegradable polymer may be contained in a weight ratio of 1:2 to 1:10.
[0019] When administered by injection, the release rate of leuprolide is adjusted at the target site, eliminating the problem of initial over-release, and the testosterone suppression effect of said leuprolide can be sustained for more than one month.
[0020] The value according to formula 2 below may be 1 to 5.
[0021]
number
[0022] Where: Microparticles containing leuprolide were administered to beagle dogs via injection, and the blood concentration of leuprolide was measured. The amount of leuprolide acetate administered to the beagle dog in one injection was 11.25 mg; C max is the maximum blood concentration of leuprolide within 24 hours after administration of the injection. C 24h is the blood concentration of leuprolide in blood collected 24 hours after administration of the injection.
[0023] A method for producing microparticles containing leuprolide according to another embodiment of the present invention includes the steps of: 1) mixing leuprolide and a biodegradable polymer to produce a first mixture; 2) dissolving a surfactant in a solvent to produce a second mixture; 3) injecting and flowing the first and second mixtures into a first microchannel and a second microchannel, respectively, having an intersection formed therein, to generate microparticles at the intersection; 4) collecting the microparticles in a water tank containing the second mixture; 5) removing the organic solvent present in the collected microparticles; and 6) washing and freeze-drying the microparticles from which the organic solvent has been removed with purified water, and the value according to the following formula 1 may be 0.5 to 2.
[0024]
number
[0025] Where: D10 is the diameter of the particle that corresponds to 10% of the maximum value in the cumulative distribution of particles, D50 is the diameter of the particle that corresponds to 50% of the maximum value in the cumulative distribution of particles, D90 is the diameter of particles that corresponds to 90% of the maximum value in a cumulative particle distribution.
[0026] When the first mixture is injected into the first microchannel, the first mixture may be injected under a pressure condition of 700 to 1,300 mbar, and then the pressure may be increased under a first condition of 10 to 30 mbar / min, and when the injection pressure condition reaches 950 to 1,500 mbar, the pressure may be increased under a second condition of 2 to 8 mbar / min.
[0027] The second mixture may be injected into the second microchannel under pressure conditions that are two to four times higher than the pressure conditions when the first mixture is injected into the first microchannel.
[0028] The step 5) may include: 5-1) a first stirring step at 15 to 20° C. for 20 to 40 minutes at a speed of 100 to 300 rpm; 5-2) a second stirring step at 30 to 40° C. for 60 to 120 minutes at a speed of 100 to 300 rpm; and 5-3) a third stirring step at 40 to 45° C. for 4 to 8 hours at a speed of 100 to 300 rpm. Effect of the Invention
[0029] When administered by injection, the present invention provides a method for reducing pain due to the small size of the microparticles, and adjusts the release rate of leuprolide at the target site to prevent initial over-release, allowing exposure to a sufficient amount of drug to exert the effects of leuprolide, and enabling the effects of leuprolide to be exerted for more than one month.
[0030] The present invention also relates to a method for producing the microparticles, which have a uniform particle size, a smooth surface, and can exhibit a leuprolide releasing effect for a long period of time. [Brief description of the drawings]
[0031] [Figure 1] FIG. 1 is a SEM photograph of a microparticle according to one embodiment of the present invention. [Diagram 2] FIG. 2 is a SEM photograph of a microparticle according to one embodiment of the present invention. [Diagram 3] FIG. 3 is a SEM photograph of a microparticle according to one embodiment of the present invention. [Figure 4] FIG. 4 is a SEM photograph of a microparticle according to one embodiment of the present invention. [Diagram 5] FIG. 5 is a SEM photograph of a microparticle according to one embodiment of the present invention. [Figure 6] FIG. 6 is a SEM photograph of a microparticle according to one embodiment of the present invention. [Figure 7] FIG. 7 shows the PK-PD results after the microparticles according to an embodiment of the present invention were administered to beagle dogs via injection. [Figure 8] FIG. 8 shows the PK-PD results after the microparticles according to an embodiment of the present invention were administered to beagle dogs via injection. [Figure 9] FIG. 9 shows the PD results after the microparticles according to one embodiment of the present invention were administered to beagle dogs via injection. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0032] The present invention relates to microparticles containing leuprolide, which contain leuprolide and a biodegradable polymer, and have an average diameter of 40 to 100 μm and a value of 0.5 to 2 according to the following formula 1:
[0033]
number
[0034] Where: D10 is the diameter of the particle that corresponds to 10% of the maximum value in the cumulative distribution of particles, D50 is the diameter of the particle that corresponds to 50% of the maximum value in the cumulative distribution of particles, D90 is the diameter of particles that corresponds to 90% of the maximum value in a cumulative particle distribution.
[0035] DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS The present invention may, however, be embodied in many different forms and should not be construed as limited to the embodiments set forth herein.
[0036] In the present invention, "leuprolide" may include 5-Oxo-L-prolyl-Lhistidyl-L-tryptophanyl-L-seryl-L-tyrosyl-D-leucyl-L-leucyl-L-arginyl-L-prolylethylamide and its pharma- ceutical acceptable salts. Leuprolide may also be expressed as leuprorelin, and regardless of the notation, leuprolide and its pharma- ceutical acceptable salts may be used.
[0037] In the present invention, "pharmaceutical acceptable" means something that is physiologically tolerable and does not normally cause an allergic reaction or a similar reaction when administered to humans.
[0038] In the present invention, the term "pharmaceutical acceptable salt" refers to an acid addition salt formed with a pharmaceutical acceptable free acid. The free acid may be an organic acid or an inorganic acid. The organic acid may include, but is not limited to, citric acid, acetic acid, lactic acid, stannic acid, maleic acid, fumaric acid, formic acid, propionic acid, oxalic acid, trifluoroacetic acid, benzoic acid, gluconic acid, metasulfonic acid, glycolic acid, succinic acid, 4-toluenesulfonic acid, glutamic acid, and aspartic acid. The inorganic acid may include, but is not limited to, hydrochloric acid, bromic acid, sulfuric acid, and phosphoric acid.
[0039] The leuprolide-containing microparticles according to one embodiment of the present invention include leuprolide and a biodegradable polymer, and the average diameter of the microparticles is 40 to 100 μm, and the value according to the following formula 1 may be 0.5 to 2.
[0040]
number
[0041] Where: D10 is the diameter of the particle that corresponds to 10% of the maximum value in the cumulative distribution of particles, D50 is the diameter of the particle that corresponds to 50% of the maximum value in the cumulative distribution of particles, D90 is the diameter of particles that corresponds to 90% of the maximum value in a cumulative particle distribution.
[0042] The D10, D50 and D90 refer to values corresponding to 10%, 50% and 90% of the maximum value in the cumulative distribution when the diameter of the microparticle is measured.
[0043] The above formula 1 defines the average particle diameter in claim 1 and also defines the ratio of (D90-D50) and (D50-D10), and determines the degree of uniform particle distribution by checking the ratio of the difference between the diameter of particles corresponding to 90% and the diameter of particles corresponding to 50%, and the difference between the diameter of particles corresponding to 50% and the diameter of particles corresponding to 10%, with respect to the maximum value of the cumulative distribution of particles within the average particle distribution, and the closer the value is to 1, the more uniform the distribution width is.
[0044] Formula 1 of the present invention is for more clearly confirming the size distribution of microparticles, and the value according to formula 1 may be 0.5 to 2, 0.7 to 1.5, or 0.9 to 1.3. When the value according to formula 1 is satisfied and the average diameter of the microparticles is 40 to 100 μm, it means that the size of the microparticles is distributed close to the average diameter value. This means that microparticles of uniform size are injected into the body through injection, and the microparticles having uniform sizes are biodegraded to a similar extent, and the biodegradation of the microparticles can show the effect of releasing leuprolide.
[0045] That is, the release degree of leuprolide in the body of microparticles containing leuprolide is closely related to the particle size and specific surface area, and in order to increase the specific surface area, it is essential to use microparticles with a uniform diameter. As described above, by using microparticles with a very uniform particle size, it is possible to prevent initial over-release when injected into the body, and to exhibit a long-term sustained release effect of leuprolide, so that the effect of leuprolide can be exerted for more than one month.
[0046] The leuprolide and the biodegradable polymer may be contained in a weight ratio of 1:2 to 1:10, preferably 1:2 to 1:8, and more preferably 1:4 to 1:7. When mixed within the above range, the leuprolide can be released continuously for a long period of time due to the degradation of the biodegradable polymer.
[0047] The biodegradable polymer is selected from the group consisting of polylactic acid, polylactide, polylactic-co-glycolic acid, polylactide-co-glycolide (PLGA), polyphosphazine, polyiminocarbonate, polyphosphoester, polyanhydride, polyorthoester, polycaprolactone, polyhydroxyvalerate, polyhydroxybutyrate, polyamino acid, and combinations thereof, and is preferably polylactide-co-glycolide (PLGA) or polylactide, but is not limited to the above examples.
[0048] In another embodiment of the present invention, the leuprolide-containing microparticles may have a value of 1 to 15 according to the following formula 2.
[0049]
number
[0050] Where: Microparticles containing leuprolide were administered to beagle dogs via injection, and the blood concentration of leuprolide was measured. The amount of leuprolide acetate administered to the beagle dog in one injection was 11.25 mg; C max is the maximum blood concentration of leuprolide within 24 hours after administration of the injection. C 24h is the blood concentration of leuprolide in blood collected 24 hours after administration of the injection.
[0051] As mentioned above, it is known that initial over-release is an essential element for leuprolide to exert its pharmacological effect. That is, when administered as an injection, a high initial drug release rate is required so that the blood concentration of leuprolide can be at a high level at the beginning. That is, it is known that in order to exert a sufficient pharmacological effect as an LHRH agonist, a high drug release rate must be exhibited at the beginning of administration, and therefore, the dosage form for leuprolide currently on the market is manufactured so as to exhibit a high initial drug release rate.
[0052] On the other hand, not only leuprolide but most other drugs can cause side effects when overexposed, i.e., excessive release of leuprolide can cause side effects such as nausea, pain around the injection site, headache, urinary problems, and joint pain.
[0053] Despite the risk of side effects as described above, it is known that in order for leuprolide to exert its pharmacological effect, an initial over-release of the drug is necessary when administered by injection.
[0054] Therefore, in the present invention, when the value according to the above formula 2 is satisfied, the maximum blood concentration value within 24 hours can be lowered compared to conventional leuprolide dosage forms, and a sustained release effect of leuprolide can be exhibited for a long period of time.
[0055] That is, in order to derive the value according to the above formula 2, a commercially available product was purchased and the same experiment was performed, and it was confirmed that the value was 50 to 60, which is a high value. In contrast, when the microparticles of the present invention were administered, it was confirmed that the value was 1 to 15, preferably 2 to 10, and more preferably 3 to 8, which is a large difference.
[0056] The difference in the above results is due to the fact that it is known that in conventional leuprolide, an initial over-release is necessary to exert its effect, and the molecular value of formula 2 is confirmed to be large, whereas the microparticles of the present invention prevent the initial over-release while exerting the pharmacological effect of leuprolide and deriving an optimal blood concentration that can exert the effect of drug release over a long period of time.
[0057] The value calculated by the above formula 2 includes the maximum blood concentration of leuprolide in the numerator, and the higher the maximum blood concentration, the higher the value of formula 2 may be. Conversely, the denominator, C 24h If the value of is small, the value of Eq. 2 may be large.
[0058] As mentioned above, when the maximum blood concentration of leuprolide increases, the value of formula 2 increases. This means that an initial over-release occurs when the drug is used as an injection. 24h Since the value of is small, it can be said that a large value of Equation 2 means that the drug release effect cannot be exhibited for a long period of time.
[0059] Therefore, when the value of the above formula 2 is within the range of the present invention, it can be said that the initial excessive release of leuprolide can be prevented, the pharmaceutical efficacy of leuprolide can be exerted, and when administered by injection, the pharmaceutical efficacy of leuprolide can be sustained for more than one month.
[0060] A method for producing microparticles containing leuprolide according to another embodiment of the present invention includes the steps of: 1) mixing leuprolide and a biodegradable polymer to produce a first mixture; 2) dissolving a surfactant in a solvent to produce a second mixture; 3) injecting and flowing the first and second mixtures into a first microchannel and a second microchannel, respectively, having an intersection formed therein, to generate microparticles at the intersection; 4) collecting the microparticles in a water tank containing the second mixture; 5) removing the organic solvent present in the collected microparticles; and 6) washing and freeze-drying the microparticles from which the organic solvent has been removed with purified water, and the value according to the following formula 1 may be 0.5 to 2.
[0061]
number
[0062] Where: D10 is the diameter of the particle that corresponds to 10% of the maximum value in the cumulative distribution of particles, D50 is the diameter of the particle that corresponds to 50% of the maximum value in the cumulative distribution of particles, D90 is the diameter of particles that corresponds to 90% of the maximum value in a cumulative particle distribution.
[0063] Step 1) is a step of preparing a first mixture, in which leuprolide and a biodegradable polymer are dissolved in an organic solvent to prepare a first mixture, and the biodegradable polymer is selected from the group consisting of polylactic acid, polylactide, polylactic-co-glycolic acid, polylactide-co-glycolide (PLGA), polyphosphazine, polyiminocarbonate, polyphosphoester, polyanhydride, polyorthoester, polycaprolactone, polyhydroxyvalerate, polyhydroxybutyrate, polyamino acid, and combinations thereof, preferably polylactide-co-glycolide (PLGA), but not limited to the above examples.
[0064] In addition, the organic solvent is immiscible with water, and is, for example, any one or more selected from the group consisting of chloroform, chloroethane, dichloroethane, trichloroethane, and mixtures thereof, and is preferably dichloromethane, but is not limited to the examples. It can be said that any organic solvent that is capable of dissolving the biodegradable polymer and leuprolide and that can be easily selected by a person skilled in the art is not limited to the above examples and can be used.
[0065] The step 1) is to prepare a first mixture in which leuprolide and a biodegradable polymer are dissolved, and the solvent is an organic solvent as described above, which uses the solubility properties of leuprolide and a biodegradable polymer to completely dissolve them in the organic solvent.
[0066] More specifically, leuprolide acetate is dissolved in a first solvent, and a biodegradable polymer is dissolved in a second solvent, and then the mixture of leuprolide acetate dissolved in the first solvent and the mixture of biodegradable polymer dissolved in the second solvent are mixed to prepare a first mixture.
[0067] The first mixture contains leuprolide and biodegradable polymer in a weight ratio of 1:2 to 1:10. The weight ratio is preferably 1:2 to 1:8, and more preferably 1:4 to 1:7. When the weight ratio of leuprolide and biodegradable polymer is less than 1:2, i.e., when the biodegradable polymer is contained in a ratio less than the above weight ratio, the weight ratio of the biodegradable polymer is small compared to the weight of leuprolide, and it is difficult to prepare sustained release particles in which leuprolide is uniformly distributed in spherical biodegradable polymer particles. When the weight ratio of the biodegradable polymer and leuprolide is more than 1:10, i.e., when the biodegradable polymer is contained in an amount greater than the above weight ratio, the content of leuprolide in the sustained release particles is low, and therefore a large amount of sustained release particles must be administered to administer the desired concentration of the drug.
[0068] More specifically, the biodegradable polymer in the first mixture is contained in an amount of 15 to 25% by weight, preferably 20% by weight, but is not limited to the above examples.
[0069] The step 2) is a step of preparing a second mixture, and the second mixture is prepared by dissolving a surfactant in water. The surfactant can be used without any limitation as long as it can help the biodegradable polymer solution to form a stable emulsion. Specifically, the surfactant is any one or more selected from the group consisting of nonionic surfactants, anionic surfactants, cationic surfactants, and mixtures thereof, more specifically, any one or more selected from the group consisting of methylcellulose, polyvinylpyrrolidone, lecithin, gelatin, polyvinyl alcohol, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene castor oil derivatives, sodium lauryl sulfate, sodium stearate, esteramines, linear diamines, aliphatic amines, and mixtures thereof, preferably polyvinyl alcohol, but not limited to the examples.
[0070] The step 3) is a step of injecting and flowing the first mixture and the second mixture into a microchannel formed on the wafer.
[0071] More specifically, the microchannel may be formed from a material selected from the group consisting of a silicone wafer or a polymer film, but the examples of the material are not limited to the above examples, and any material capable of forming a microchannel can be used.
[0072] The polymer film may be selected from the group consisting of polyimide, polyethylene, fluorinated ethylene propylene, polypropylene, polyethylene terephthalate, polyethylene naphthalate, polysulfone, and mixtures thereof, but is not limited to the above examples.
[0073] As an example, aluminum is evaporated onto a silicon wafer using an e-beam evaporator, and photoresist is patterned on the aluminum using a photolithography technique. Then, the aluminum is etched using the photoresist as a mask, and after removing the photoresist, silicon is etched by DRIE (deep ion reactive etching) using the aluminum as a mask, and after removing the aluminum, glass is bipolar-bonded onto the wafer and sealed to produce the microchannel.
[0074] The microchannel has an average diameter of 80 to 120 μm, preferably 100 μm, but is not limited to this example. If the average diameter of the microchannel is 80 μm or less, the diameter of the sustained-release particles produced may be small, less than 40 μm, which may affect effective drug release and in vivo absorption. In addition, if the size of the sustained-release particles produced exceeds 100 μm, foreign body sensation and pain may increase when administered by injection, and the particle size distribution of the produced particles becomes large, making it difficult to produce sustained-release particles with a uniform particle size.
[0075] However, the average diameter of the microchannels may vary with the range of injection pressures, and is closely related to the average diameter of the particles, but also to the injection pressures of the first and second mixtures.
[0076] In addition, the cross-sectional width w and cross-sectional height d of the microchannel are closely related to the average diameter d' of the controlled release particles to be produced. As shown in Fig. 8, the cross-sectional width w of the microchannel is in a ratio range of 0.7 to 1.3 with respect to the average diameter d' of the controlled release particles, and the cross-sectional height d of the microchannel is in a ratio range of 0.7 to 1.3 with respect to the average diameter d' of the controlled release particles.
[0077] In other words, once the average diameter d' of the controlled release particles to be produced is determined, the width w and height d of the microchannel cross section must be set in the ratio range of 0.7 to 1.3 of d' to produce controlled release particles of the desired size.
[0078] The step 3) is to flow the first mixture and the second mixture into the first microchannel and the second microchannel where an intersection is formed, under the injection pressure condition.
[0079] That is, the first mixture flows along a first microchannel, and the second mixture flows along a second microchannel shaped to form an intersection with the first microchannel, where it meets the flow of the first mixture.
[0080] More specifically, when the first mixture is injected into the first microchannel, the pressure may be increased under a first condition of 10 to 30 mbar / min after injection under a pressure condition of 700 to 1,300 mbar, and when the injection pressure condition reaches 950 to 1,500 mbar, the pressure may be increased under a second condition of 2 to 8 mbar / min.
[0081] Also, the second mixture may be injected into the second microchannel under pressure conditions that are two to four times higher than the pressure conditions under which the first mixture is injected into the first microchannel.
[0082] Specifically, in the manufacturing method using the microchannel, when the flow rates of the first mixture and the second mixture flowing inside the microchannel were set to constant values using a flow meter and the pressure was measured through feedback control, it was confirmed that the pressure required to cause the first mixture to flow through the microchannel at a constant flow rate gradually increased over time.
[0083] Therefore, by using a method in which the pressure applied to the first mixture is steadily increased to minimize variability in the flow rate and the first mixture gradually hardens inside the microchannel, problems of variation in microparticle distribution or channel blockage can be prevented and the production yield of the targeted microparticles can be increased.
[0084] In addition, the pressure conditions when injecting the first mixture and the second mixture into the microchannel are for controlling the average diameter of the produced microparticles, and if the above range is not specifically satisfied, problems may occur such that the size of the produced particles is not uniform, or the average diameter range of the microparticles of the present invention is not satisfied, or the value of Equation 1 is not satisfied.
[0085] That is, in order to make the second mixture flow at an intersection with the first mixture flow at a faster flow rate than the first mixture injected into the linear microchannel, the second mixture is flowed under a higher pressure condition.
[0086] As described above, by making the flow rates of the first mixture and the second mixture different and making the flow rate of the second mixture faster than the flow rate of the first mixture, at the point where the flow of the first mixture meets the flow of the second mixture, the second mixture, which has a relatively faster flow rate, compresses the first mixture. At this time, the repulsive force between the first mixture and the second mixture causes the biodegradable polymer and leuprolide in the first mixture to produce spherical microparticles, and more specifically, microparticles in which leuprolide is uniformly distributed in a spherical biodegradable polymer are formed.
[0087] Step 4) is a step of collecting the microparticles, and the microparticles are collected in a water bath containing the second mixture to prevent aggregation between the initially generated microparticles.
[0088] Step 4) uses the second mixture prepared in step 2), i.e., a mixed solution of surfactant and water. After preparing the second mixture in step 2), a portion of the mixture is injected into a microchannel and another portion is moved to a water tank in step 4) to prevent aggregation between the collected microparticles.
[0089] Step 5) is a step for removing the organic solvent present in the microparticles collected in the water tank, and the organic solvent present on the surface of the controlled release particles is evaporated and removed by stirring under a certain temperature condition and stirring speed. At this time, the stirring conditions are 5-1) a first stirring step at a speed of 100 to 300 rpm at 15 to 20°C for 20 to 40 minutes, 5-2) a second stirring step at a speed of 100 to 300 rpm at 30 to 40°C for 60 to 120 minutes, and 5-3) a third stirring step at a speed of 100 to 300 rpm at 40 to 45°C for 4 to 8 hours.
[0090] The stirring speed, temperature conditions and stirring duration are different between the first and second stirring steps to perform the stirring process.
[0091] As described above, the temperature condition is increased in the second stirring step compared to the first stirring step, and the temperature is increased stepwise to control the evaporation rate of the organic solvent present on the surface of the microparticles, i.e., the organic solvent present on the surface of the microparticles is gradually evaporated to produce microparticles having a smooth surface.
[0092] The temperature of the first and second mixtures when they flow through the microchannels is also 15 to 20° C., and preferably 17° C. That is, after they flow through the microchannels and form an intersection to generate microparticles, the low temperature of 15 to 20° C. is maintained until the collected microparticles are first stirred. Only by maintaining a low temperature during the microparticle production process can spherical particles be produced and maintained. That is, if the low temperature conditions are not met, it is difficult to produce uniform spherical particles.
[0093] Thereafter, the second and third stirring steps gradually increase the temperature and increase the stirring time, so that the organic solvent present on the surface of the microparticles gradually evaporates, thereby minimizing the effect on the surface of the microparticles caused by the evaporation of the organic solvent on the surface. That is, if the organic solvent evaporates rapidly, the surface of the microparticles may become rough and not smooth due to the evaporation of the organic solvent. To prevent this problem, the temperature condition may be gradually increased and the time for performing the stirring step may be increased to adjust the evaporation rate of the organic solvent, as described above, and the surface roughness of the manufactured microparticles may be controlled by adjusting the evaporation rate of the organic solvent.
[0094] Finally, step 6) is a step of washing and drying the microparticles, in which the microparticles are stirred to remove all organic solvents from the surface, washed several times with sterilized and filtered purified water to remove surfactants remaining on the microparticles, and then freeze-dried.
[0095] The final microparticles are spherical microparticles made of biodegradable polymer in which leuprolide is uniformly distributed, and contain leuprolide and biodegradable polymer in a weight ratio of 1:2 to 1:10.
[0096] The weight ratio of leuprolide and biodegradable polymer contained in the microparticles is the same as the weight ratio in the first mixture, which is achieved by producing microparticles and then evaporating and removing all of the organic solvent to produce microparticles containing leuprolide and biodegradable polymer in the same weight ratio as in the first mixture.
[0097] An injectable composition containing microparticles containing leuprolide according to another embodiment of the present invention may include microparticles containing leuprolide and a suspending solvent.
[0098] The injectable composition is in the form of microparticles uniformly contained in a suspension solvent, and when the injectable composition is administered, the microparticles themselves are injected into the body, thereby providing a long-term administration effect of leuprolide.
[0099] More specifically, when the microparticles are injected into the body, the effect of releasing leuprolide is exerted by the decomposition of the biodegradable polymer. At this time, since the microparticles of the present invention are in the form of a uniform mixture of the biodegradable polymer and leuprolide, the effect of administering a constant concentration of leuprolide for a long period of time can be exerted.
[0100] That is, the injectable composition of the present invention can be used to continuously release leuprolide in the body for more than one month after a single injection, thereby solving the problem of having to take the drug every day and increasing the convenience of the user. More specifically, when the injectable composition of the present invention is used, it can be provided as a long-lasting dosage form capable of continuously releasing leuprolide for one month, a long-lasting dosage form capable of continuously releasing leuprolide for three months, or a long-lasting dosage form capable of continuously releasing leuprolide for six months.
[0101] The suspension medium comprises an isotonicity agent, a suspending agent and a solvent.
[0102] More specifically, the tonicity agent may be selected from the group consisting of D-mannitol, maltitol, sorbitol, lactitol, xylitol, sodium chloride, and mixtures thereof, preferably D-mannitol, but is not limited to the above examples.
[0103] The suspending agent may be sodium carboxymethylcellulose, polysorbate 80, starch, starch derivatives, polyhydric alcohols, chitosan, chitosan derivatives, cellulose, cellulose derivatives, collagen, gelatin, hyaluronic acid (HA), alginic acid, algin, pectin, carrageenan, chondroitin, chondroitin sulfate, dextran, dextran sulfate, polylysine, titin, fibrin, agarose, fluran, xanthan gum, etc. The preferred examples of the antibacterial agent are selected from the group consisting of sodium carboxymethylcellulose and polysorbate 80, but are not limited to these.
[0104] The solvent may be water for injection, and any solvent that can be used as water for injection may be used without any limitation.
[0105] Manufacturing Example 1 Preparation of Leuprolide-Containing Microparticles Leuprolide acetate was dissolved in dimethyl sulfoxide to prepare an API mixture. Poly(lactide-co-glycolide) (PLGA) was dissolved in dichloromethane to prepare a biodegradable polymer mixture.
[0106] The API mixture and the biodegradable polymer mixture were mixed to prepare a first mixture, in which the weight ratio of leuprolide acetate to the biodegradable polymer in the first mixture was 1:5.
[0107] Polyvinyl alcohol, a surfactant, was mixed with water to produce a second mixture containing 0.5% by weight of polyvinyl alcohol.
[0108] The first and second mixtures were injected and flowed into a microchannel formed on a silicon wafer.
[0109] In order to flow the first and second mixtures at a constant flow rate, the first mixture was flowed under a pressure condition of 1000 mbar, which was increased at a constant rate of 20 mbar per minute, and then when it reached 1200 mbar, the pressure was changed to an increase rate of 7 mbar per minute, and the second mixture was flowed under a pressure condition of 3000 mbar. The temperature condition was 17° C. and the stirring speed was maintained at 300 rpm.
[0110] The microparticles generated at the intersection where the first mixture flow and the second mixture flow meet were collected in a water tank containing the second mixture. The microparticles collected in the water tank were first stirred at 300 rpm for 30 minutes at 17°C, the temperature was increased to 38°C, the second stirring was performed at 400 rpm for 1 hour, and then the temperature was increased to 45°C, and the third stirring was performed at 500 rpm for 3 hours.
[0111] After the stirring was completed, the microparticles were washed several times with sterilized and filtered purified water and freeze-dried to produce microparticles.
[0112] Manufacturing Example 2 Microparticles were prepared in the same manner as in Preparation Example 1, except that poly(lactide-co-glycolide) (PLGA) and polylactic acid (PLA) were dissolved in dichloromethane in a weight ratio of 1.7:18.3 to prepare a biodegradable polymer mixture.
[0113] Production Example 3 Microparticles were produced in the same manner as in Production Example 1, except that polylactic acid (PLA) was dissolved in dichloromethane as the biodegradable polymer to produce a biodegradable polymer mixture.
[0114] Thereafter, the microparticles of Production Example 1 and the microparticles of Production Example 3 were mixed in a weight ratio of 1:3.
[0115] Production Example 4 The microparticles of Production Example 1 and the microparticles of Production Example 3 were mixed in a weight ratio of 1:4.
[0116] Production Example 5 Microparticles were prepared in the same manner as in Preparation Example 1, except that the weight ratio of leuprolide acetate and biodegradable polymer in the first mixture was 1:4.
[0117] Production Example 6 Microparticles were prepared in the same manner as in Preparation Example 1, except that the weight ratio of leuprolide acetate and biodegradable polymer in the first mixture was 1:7.
[0118] Production Example 7 Microparticles were prepared in the same manner as in Preparation Example 1, except that the weight ratio of leuprolide acetate and the biodegradable polymer in the first mixture was 1:2.
[0119] Comparative Example 1 In the comparative example, a commercially available Leuprorelin DPS injection (Takeda Pharmaceutical, Korea) was used. Specific information about the Leuprorelin DPS injection is as follows:
[0120] [Table 1]
[0121] The microparticles were prepared in an injectable form using the following suspension media:
[0122] [Table 2]
[0123] Experimental Example 1 Examination of the properties of microparticles In order to examine the properties of the microparticles in the Preparation Examples and Comparative Examples, the properties of the prepared microparticles were examined through SEM photographs.
[0124] 1 and 2 are SEM photographs of the microparticles of Production Examples 1 to 7, and it can be seen that perfectly spherical sustained release particles are produced.
[0125] 3 and 4 are SEM photographs of Leuprorelin DPS Injection of Comparative Example 1, and it can be seen that dispersed particles are mixed in.
[0126] To specifically confirm the diameter of the microparticles, an analysis was performed on Preparation Example 1, Preparation Example 2, and Comparative Example 1 using a Microtrac particle size analyzer.
[0127] [Table 3]
[0128] According to Table 3, it can be seen that the particle diameters of D10 to D95 of Comparative Example 1 are variously distributed from 5.88 μm to 52.07 μm, which is because the composition contains microparticles of various sizes for initial over-release, as described above.
[0129] In contrast, the microparticles of the present invention have diameters of 55.29 μm to 73.09 μm (Production Example 1) and 72.26 μm to 95.78 μm (Production Example 2), confirming that the particle diameter distribution is uniform. Also, it can be confirmed that the values according to the above formula are close to 1 in Production Examples 1 and 2, whereas Comparative Example 1 has a value greater than 1, confirming that the size distribution is not uniform.
[0130] As another comparative example, a commercially available leuprolide formulation was purchased, and the particle properties of this were confirmed by SEM photography.
[0131] Figure 5 relates to Lorelin Depot Injection (Dongguk Pharmaceutical), and Figure 7 relates to Rupee Adepot Injection (Daekwon Pharmaceutical).
[0132] 5 and 6, it can be seen that the particle sizes are not uniform but are distributed in a variety of ways, and the particle surfaces are not smooth but are rough.
[0133] Experimental Example 2 Pharmacokinetic characterization The pharmacokinetic evaluation of the leuprolide-containing microparticles of the present invention and an injection formulation containing the same was confirmed.
[0134] The microparticles are a sustained release dosage form for more than one month, and it was confirmed whether they could sustain the pharmacological effect of leuprolide by continuously releasing leuprolide for one month after injection.
[0135] The amount of leuprolide acetate administered to mice via the microparticles of the present invention is 0.1 mg / kg.
[0136] To confirm the blood concentration in the body, 10 mice were injected and blood samples were taken and analyzed at 24h, 18h, 12h, 6h, 0h, 0.5h, 1h, 3h, 6h, 1day, 2days, 3days, 4days, 1week, 2weeks, 3weeks and 4weeks after the injection was administered to the mice. The PK values below are the average PK values for 10 mice.
[0137] [Table 4]
[0138] In order to confirm whether the drug is sustained-released for 3 months, the same experiment was conducted, except that the amount of leuprolide acetate administered to mice through the microparticles, which are the sustained-release dosage form for 3 months or more of the present invention, was adjusted to 0.3 mg / kg. The same experiment was also conducted for Comparative Example 1.
[0139] The experimental results are shown in Table 5 below.
[0140] [Table 5]
[0141] Said C max is the maximum blood concentration of leuprolide within 24 hours after administration of the injection, and 24h is the blood concentration of leuprolide in blood collected 24 hours after administration of the injection.
[0142] As can be seen from Tables 4 and 5 above, the microparticles of the present invention, in both the 1-month dosage form and the 3-month dosage form, do not exhibit initial over-release, and leuprolide is continuously released for 1 month or 3 months.
[0143] The results of calculating the values according to the above formula showed that the 1-month dosage form had a value of 2.79 and the 3-month dosage form had a value of 5.55, which are within the range of the present invention. However, the value of Comparative Example 1 was 18.91, which is outside the range of the present invention.
[0144] Also, it can be confirmed through experiments that Comparative Example 1 has more initial over-emission than the present invention.
[0145] Experimental Example 3 Pharmacokinetic characterization The pharmacokinetic evaluation of the leuprolide-containing microparticles of the present invention and an injection formulation containing the same was confirmed.
[0146] For the evaluation, the dosage forms of Comparative Example 1 and Preparation Example 2 of the present invention were administered to beagle dogs, blood was collected, and the blood concentration of leuprolide (PK) and blood concentration of testosterone (PD) were measured.
[0147] The injection containing the microparticles of Preparation 1 used as the 3-month or longer sustained release dosage form was 92.64 mg in total, and contained 11.25 mg of leuprolide. In Comparative Example 1, 11.25 mg of Leuprolide DPS Injection was administered to a beagle dog.
[0148] For the experiment, Production Example 1 and Comparative Example 1 were administered to five beagle dogs each, and the administration route was intravenous injection.
[0149] Blood samples were collected from beagle dogs before administration of Manufacturing Example 1 and Comparative Example 1, at 24 hours, 18 hours, 12 hours, 6 hours, and 0 hours, and at 0 hours, 0.25 hours, 0.5 hours, 1 hour, 2 hours, 3 hours, 6 hours, 12 hours, 1 day, 2 days, 3 days, 4 days, 1 week, 2 weeks, 3 weeks, 4 weeks, 6 weeks, 8 weeks, 12 weeks, 13 weeks, and 14 weeks after administration of Manufacturing Example 1 and Comparative Example 1 to beagle dogs, and analyzed.
[0150] After blood sampling, the average values of PK and PD for five beagle dogs were calculated. The experimental results are shown in Table 6 and Figures 7 to 9 below.
[0151] [Table 6]
[0152] Said C max is the maximum blood concentration of leuprolide within 24 hours after administration of the injection, and 24h is the blood concentration of leuprolide in blood collected 24 hours after administration of the injection.
[0153] According to the above experimental results, the PK measurement results of the injection containing the microparticles of the present invention showed that the maximum blood concentration of leuprolide 24 hours after administration of the injection was 0.407ng / ml, whereas it was 98.570ng / ml in Comparative Example 1, demonstrating a large difference. Thus, the value according to the above formula was confirmed to be 3.42 in the present invention and 52.68 in Comparative Example 1, demonstrating a large difference.
[0154] In addition, according to the results of the PD measurement, it was confirmed that the microparticles of the present invention exhibited a castration effect of 0.5 ng / ml after 6 weeks, whereas the microparticles of Comparative Example 1 did not exhibit a castration effect below 0.5 ng / ml, confirming that no substantial castration effect was observed.
[0155] 9 is a comparison result of confirming the PD value after administering Preparation 2 and Comparative Example 1, and it can be confirmed that the PD value of Preparation 2 shows that the testosterone value is 0.5 ng / ml or less after 5 weeks, and that the effect of leuprolide is exerted. In contrast, in the case of Comparative Example 1, the blood testosterone value was confirmed to be 0.5 ng / ml or more after 14 weeks, and it can be confirmed that the effect of leuprolide is not exerted.
[0156] Although the preferred embodiments of the present invention have been described in detail above, the scope of the present invention is not limited thereto, and various modifications and improvements made by those skilled in the art using the basic concept of the present invention defined in the following claims also belong to the scope of the present invention. [Industrial Applicability]
[0157] The present invention relates to microparticles containing leuprolide and a method for producing the same.
Claims
1. comprising leuprolide and a biodegradable polymer, The average diameter of the microparticles is between 40 and 100 μm; The value according to the following formula 1 is 0.5 to 2, Microparticles containing leuprolide. [0010] Where: D10 is the diameter of particles that corresponds to 10% of the maximum value in the cumulative distribution of particles, D50 is the diameter of particles that corresponds to 50% of the maximum value in the cumulative distribution of particles, D90 is the diameter of particles that corresponds to 90% of the maximum value in a cumulative distribution of particles.
2. The leuprolide and the biodegradable polymer are contained in a weight ratio of 1:2 to 1:
10.
2. A microparticle comprising the leuprolide of claim 1.
3. When administered by injection, the release rate of leuprolide is adjusted at the target site, eliminating the problem of initial over-release. The testosterone suppression effect of the leuprolide lasts for more than one month.
2. A microparticle comprising the leuprolide of claim 1.
4. The value according to the following formula 2 is 1 to 15:
2. A microparticle comprising the leuprolide of claim 1. [0025] Where: Microparticles containing leuprolide were administered to beagle dogs via injection, and the blood concentration of leuprolide was measured. The amount of leuprolide acetate administered to the beagle dog per injection was 11.25 mg; C max is the maximum blood concentration of leuprolide within 24 hours after administration of the injection, C 24h is the blood concentration of leuprolide in blood collected 24 hours after administration of the injection.
5. 1) mixing leuprolide and a biodegradable polymer to produce a first mixture; 2) dissolving a surfactant in a solvent to produce a second mixture; 3) injecting and flowing the first mixture and the second mixture into a first microchannel and a second microchannel, respectively, where an intersection is formed, to generate microparticles at the intersection; 4) collecting the microparticles in a water bath containing the second mixture; 5) removing the organic solvent present on the collected microparticles; 6) washing the microparticles from which the organic solvent has been removed with purified water and freeze-drying; The value according to the following formula 1 is 0.5 to 2, A method for making microparticles comprising leuprolide. [0030] Where: D10 is the diameter of particles that corresponds to 10% of the maximum value in the cumulative distribution of particles, D50 is the diameter of particles that corresponds to 50% of the maximum value in the cumulative distribution of particles, D90 is the diameter of particles that corresponds to 90% of the maximum value in a cumulative distribution of particles.
6. The first mixture is injected into the first microchannel under a pressure condition of 700 to 1,300 mbar, and then the pressure is increased under a first condition of 10 to 30 mbar / min; When the injection pressure condition reaches 950 to 1,500 mbar, increasing the pressure at a second condition of 2 to 8 mbar / min; A method for producing microparticles containing leuprolide according to claim 5.
7. The second mixture is injected into the second microchannel under pressure conditions that are 2 to 4 times higher than the pressure conditions when the first mixture is injected into the first microchannel. A method for producing microparticles containing leuprolide according to claim 5.
8. The step 5) comprises: 5-1) performing a first stirring step at a speed of 100 to 300 rpm for 20 to 40 minutes at 15 to 20°C; 5-2) Secondary stirring at 30 to 40° C. for 60 to 120 minutes at a speed of 100 to 300 rpm; 5-3) Stirring the mixture at 40 to 45° C. for 4 to 8 hours at a speed of 100 to 300 rpm for the third time. A method for producing microparticles containing leuprolide according to claim 5.
Citation Information
Patent Citations
Polymeric delivery formulations of leuprolide withimproved efficacy
KR1020030064401A
